Elsevier

Clinical Therapeutics

Volume 26, Issue 7, July 2004, Pages 951-979
Clinical Therapeutics

A treatment algorithm for neuropathic pain

https://doi.org/10.1016/S0149-2918(04)90171-3Get rights and content

Abstract

Background: Neuropathic pain is a chronic pain syndrome caused by drug-, disease-, or injury-induced damage or destruction of sensory neurons within the dorsal root ganglia of the peripheral nervous system. Characteristic clinical symptoms include the feeling of pins and needles; burning, shooting, and/or stabbing pain with or without throbbing; and numbness. Neuronal hyperexcitability represents the hallmark cellular mechanism involved in the underlying pathophysiology of neuropathic pain. Although the primary goal is to alleviate pain, clinicians recognize that even the most appropriate treatment strategy may be, at best, only able to reduce pain to a more tolerable level.

Objective: The purpose of this review is to propose a treatment algorithm for neuropathic pain that health care professionals can logically follow and adapt to the specific needs of each patient. The algorithm is intended to serve as a general guide to assist clinicians in optimizing available therapeutic options.

Methods: A comprehensive review of the literature using the PubMed, MEDLINE, Cochrane, and Toxnet databases was conducted to design and develop a novel treatment algorithm for neuropathic pain that encompasses agents from several drug classes, including antidepressants, antiepileptic drugs, topical antineuralgic agents, narcotics, and analgesics, as well as various treatment options for refractory cases.

Results: Any of the agents in the first-line drug classes (tricyclic antidepressants, antiepileptic drugs, topical antineuralgics, analgesics) may be used as a starting point in the treatment of neuropathic pain. If a patient does not respond to treatment with at least 3 different agents within a drug class, agents from a second drug class may be tried. When all first-line options have been exhausted, narcotic analgesics or refractory treatment options may provide some benefit. Patients who do not respond to monotherapy with any of the first- or second-line agents may respond to combination therapy or may be candidates for referral to a pain clinic. Because the techniques used at pain clinics tend to be invasive, referrals to these clinics should be reserved for patients who are truly refractory to all forms of pharmacotherapy.

Conclusions: Neuropathic pain continues to be one of the most difficult pain conditions to treat. With the proposed algorithm, clinicians will have a framework from which to design a pain treatment protocol appropriate for each patient. The algorithm will also help streamline referrals to specialized pain clinics, thereby reducing waiting list times for patients who are truly refractory to traditional pharmacotherapy.

References (213)

  • M.B. Max et al.

    Efficacy of desipramine in painful diabetic neuropathy: A placebo-controlled trial

    Pain

    (1991)
  • A. Einarson et al.

    The safety of dextromethorphan in pregnancy: Results of a controlled study

    Chest

    (2001)
  • D.R. Ure et al.

    Preservation of neurologic function during inflammatory demyelination correlates with axon sparing in a mouse model of multiple sclerosis

    Neuroscience

    (2002)
  • J. Sawynok et al.

    Peripheral antinociceptive action of amitriptyline in the rat formalin test: Involvement of adenosine

    Pain

    (1999)
  • P. Popik et al.

    Chronic treatment with antidepressants affects glycine/NMDA receptor function: Behavioral evidence

    Neuropharmacology

    (2000)
  • T.P. Enggaard et al.

    The analgesic effect of codeine as compared to imipramine in different human experimental pain models

    Pain

    (2001)
  • A.H. Dickenson et al.

    Neurobiology of neuropathic pain: Mode of action of anticonvulsants

    Eur J Pain

    (2002)
  • R.D. MacPherson

    The pharmacological basis of contemporary pain management

    Pharmacol Ther

    (2000)
  • B. Soderpalm

    Anticonvulsants: Aspects of their mechanisms of action

    Eur J Pain

    (2002)
  • C.P. Taylor et al.

    A summary of mechanistic hypotheses of gabapentin pharmacology

    Epilepsy Res

    (1998)
  • W.D. Willis

    The pain system. The neural basis of nociceptive transmission in the mammalian nervous system

    Pain Headache

    (1985)
  • S.J. Stankus et al.

    Management of herpes zoster (shingles) and postherpetic neuralgia

    Am Fam Physician

    (2000)
  • H.W. Maloni

    Pain in multiple sclerosis: An overview of its nature and management

    J Neurosci Nurs

    (2000)
  • R. Won et al.

    Role of different peripheral components in the expression of neuropathic pain syndrome

    Yonsei Med J

    (2000)
  • B.A. Winkelstein et al.

    Nerve injury proximal or distal to the DRG induces similar spinal glial activation and selective cytokine expression but differential behavioral responses to pharmacologic treatment

    J Comp Neurol

    (2001)
  • H. Honma et al.

    Acute glucose deprivation leads to apoptosis in a cell model of acute diabetic neuropathy

    J Peripher Nerv Syst

    (2003)
  • S. Srinivasan et al.

    Diabetic peripheral neuropathy: Evidence for apoptosis and associated mitochondrial dysfunction

    Diabetes

    (2000)
  • A.M. Schmeichel et al.

    Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy

    Diabetes

    (2003)
  • W.M. Campana et al.

    Exogenous erythropoeitin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury

    Eur J Neurosci

    (2003)
  • C.J. Woolf et al.

    Peripheral nerve injury triggers central sprouting of myelinated afferents

    Nature

    (1992)
  • B.C. Hains et al.

    Upregulation of sodium channel Nav1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury

    J Neurosci

    (2003)
  • L. Sherwood

    Human Physiology: From Cells to Systems

    (2001)
  • F.H. Lopes Da Silva et al.
  • A.I. Vinik

    Diabetic Neuropathy: A Small-Fiber Disease

  • M. Koltzenburg et al.

    Neuropathic pain

    Curr. Opin Neurol.

    (2001)
  • W.K. Ilse

    Neuropathic pain: Mechanisms, diagnosis and treatment

    Can J Continuing Med Education

    (2002)
  • G. McCleane

    Pharmacological management of neuropathic pain

    CNS Drugs

    (2003)
  • M.S. Wallace

    Pharmacologic treatment of neuropathic pain

    Curr Pain Headache Rep

    (2001)
  • S. Abdi et al.

    The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain

    Anesth Analg

    (1998)
  • M.R. Semenchuk et al.

    Efficacy of sustained-release bupropion in neuropathic pain: An open-label study

    Clin J Pain

    (2000)
  • P.G. Jensen et al.

    Management of painful diabetic neuropathy

    Drugs Aging

    (2001)
  • R. Kishore-Kumar et al.

    Desipramine relieves postherpetic neuralgia

    Clin Pharmacol Ther

    (1990)
  • S.H. Richeimer et al.

    Utilization patterns of tricyclic antidepressants in a multidisciplinary pain clinic: A survey

    Clin J Pain

    (1997)
  • R.L. Barkin et al.

    Pharmacologic management of acute and chronic pain: Focus on drug interactions and patient-specific pharmacotherapeutic selection

    South Med J

    (2001)
  • M.B. Max

    Treatment of post-herpetic neuralgia: Antidepressants

    Ann Neurol

    (1994)
  • King G, Poston J, Bruce LD, eds. Ottawa: Canadian Pharmacists Association;...
  • K. Bielefeldt et al.

    Amitriptyline inhibits voltage-sensitive sodium currents in rat gastric sensory neurons

    Dig Dis Sci

    (2002)
  • P.A. Lavoie et al.

    Tricyclic antidepressants inhibit voltage-dependent calcium channels and Na(+)-Ca2+ exchange in rat brain cortex synaptosomes

    Can J Physiol Pharmacol

    (1990)
  • M.B. Max et al.

    Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood

    Neurology

    (1987)
  • Cited by (122)

    • Gabapentin and pregabalin for the treatment of chronic pruritus

      2016, Journal of the American Academy of Dermatology
    View all citing articles on Scopus
    View full text